title: Relapsed/refractory Hodgkin lymphoma: what is the best salvage therapy and do we need RIC-alloSCT?
abstract: For relapsed-refractory Hodgkin Lymphoma, standard therapy consists of salvage chemotherapy followed by autologous stem cell transplantation. Adverse risk factors at relapse include response duration less than 12 months, advanced stage, extranodal disease, "B" symptoms and anemia. There is no obvious superior salvage regimen although maintaining dose-intensity is important for optimal responses. Assessment of response to salvage using FDG-PET identifies a distinct poor risk group, especially those with extranodal disease. Either a second salvage regimen or a tandem autologous transplant may benefit some patients with residual disease post-salvage. Reduced-intensity allografting may provide durable responses for some patients relapsing post-autologous transplant.
authors.affiliation: Department of Haematology, Level 2 ICPMR, Westmead Hospital, Darcy Road, Westmead, New South Wales 2145, Australia. Electronic address: mhertzberg10@gmail.com.
authors.forename: Mark
authors.initials: M
authors.lastname: Hertzberg
mesh_terms: D000465:Algorithms; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006689:Hodgkin Disease / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D049268:Positron-Emission Tomography; D011379:Prognosis; D016879:Salvage Therapy; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D019788:Fluorodeoxyglucose F18
keywords: Autologous transplant; FDG-PET scan; Prognostic factors; RIC-alloSCT; Salvage chemotherapy